8 results

  • glyxambi

    (empagliflozin and linagliptin)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    GLYXAMBI, a combination of empagliflozin and linagliptin, is indicated to improve glycemic control in adults with type 2 diabetes mellitus alongside diet and exercise. Empagliflozin also reduces cardiovascular death risk in patients with type 2 diabetes and existing cardiovascular disease. It is not suitable for type 1 diabetes or certain conditions.

  • janumet

    (SITAGLIPTIN and METFORMIN HYDROCHLORIDE)
    Merck Sharp & Dohme LLC
    JANUMET is indicated for improving glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. It should not be used in type 1 diabetes and has not been studied in patients with a history of pancreatitis.

  • janumet

    (sitagliptin and metformin hydrochloride)
    Merck Sharp & Dohme LLC
    JANUMET XR is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It is not for use in patients with type 1 diabetes or those with a history of pancreatitis.

  • januvia

    (sitagliptin)
    Merck Sharp & Dohme LLC
    JANUVIA® is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It should not be used in type 1 diabetes and has not been studied in patients with a history of pancreatitis.

  • jentadueto

    (linagliptin and metformin hydrochloride)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    JENTADUETO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not recommended for patients with type 1 diabetes or a history of pancreatitis, as its effects in these populations are unclear.

  • steglujan

    (ertugliflozin and sitagliptin)
    Merck Sharp & Dohme LLC
    STEGLUJAN® is indicated to improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise. It is not recommended for type 1 diabetes or in patients with a history of pancreatitis due to unknown risks.

  • tradjenta

    (linagliptin)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    TRADJENTA is indicated for improving glycemic control in adults with type 2 diabetes mellitus, alongside diet and exercise. It is not recommended for type 1 diabetes patients and has not been studied in those with a history of pancreatitis.

  • trijardy xr

    (empagliflozin, linagliptin, metformin hydrochloride)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    TRIJARDY XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin within the combination helps reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. Not for type 1 diabetes.